Neos Therapeutics (NEOS) Tops Q4 EPS by 5c, Revenues Beat

Neos Therapeutics (NASDAQ: NEOS) reported Q4 EPS of ($0.23), $0.05 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $15.39 million versus the consensus estimate of $14.64 million.

“In late November 2018, we unveiled a new commercial strategy for the company that includes an optimized salesforce structure, territory realignment and expanded distribution network with a goal of increasing net margins and increasing market share for our ADHD product portfolio. We believe that this new strategy will drive the continued growth of our ADHD business and accelerate our path to profitability. This, coupled with a focus on growing our development pipeline using our proprietary microparticle technology, will create value for our stakeholders,” said Jerry McLaughlin, Chief Executive Officer of Neos Therapeutics. “We look forward to continuing to execute on this new strategy as we help more patients living with ADHD and advance toward becoming cash self-sufficient while also exploring opportunities within and beyond our current core focus in ADHD.”

For earnings history and earnings-related data on Neos Therapeutics (NEOS) click here.

You May Also Be Interested In

• Safe & Green (SGBX) Provides Update on Audit and Planned 10-K Filing
• Parke Bancorp (PKBK) Reports Q1 EPS of $0.51
• Stem, Inc. (STEM) Appoints Gerard Cunningham to its Board